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Background: Different doses of low-molecular-weight heparin (LMWH) are 
registered and used for thrombosis prophylaxis. We assessed benefits and harms of 
thrombosis prophylaxis with a predefined intermediate dose LMWH compared to 
placebo or no treatment in patients at risk of venous thromboembolism (VTE).  
Methods: We performed a systematic review with meta-analyses and trial sequential 
analyses (TSA) following The Cochrane Handbook for Systematic Reviews of 
Interventions. Medline, Cochrane CENTRAL, Web of Science, and Embase were 
searched up to December 2018. Trials were evaluated for risk of bias and quality of 
evidence was assessed following the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.  
Results: Seventy randomized trials with 34.046 patients were included. Eighteen 
(26%) had overall low risk of bias. There was a small statistically significant effect of 
LMWH on all-cause mortality (risk ratio (RR) 0.96; trial sequential analysis-adjusted 
confidence interval (TSA-adjusted CI) 0.94-0.98) which disappeared in sensitivity 
analyses excluding ambulatory cancer patients (RR 0.99; TSA-adjusted CI 0.84-
1.16). There was moderate quality evidence for a statistically significant beneficial 
effect on symptomatic VTE (odds ratio (OR) 0.59; TSA-adjusted CI 0.53-0.67; 
Number Needed to Treat (NNT) 76; 95%CI 60-106) and a statistically significant 
harmful effect on major bleeding (peto OR 1.66; TSA-adjusted CI 1.31-2.10; Number 
Needed to Harm (NNH) 212; 95%CI 142-393). There were no significant intervention 
effects on serious adverse events.  
Conclusion: The use of intermediate dose LMWH for thrombosis prophylaxis 
compared to placebo or no treatment was associated with a small statistically 
significant reduction of all-cause mortality that disappeared in sensitivity analyses 
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excluding trials that evaluated LMWH for anticancer treatment. Intermediate dose 





Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is a frequent cause of morbidity and mortality.1 Commonly 
recognized risk factors for VTE in acutely ill patients include age, active cancer, 
previous VTE, thrombophilia, reduced mobility, recent trauma or surgery, heart 
and/or respiratory failure, stroke, and sepsis.2 
 
The American College of Chest Physicians (ACCP) guidelines recommend the use of 
mechanical or pharmacological thrombosis prophylaxis for surgical and acutely ill 
medical patients at high risk of thromboembolism.3 Multiple pharmacological agents 
such as unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are 
available for this indication. Several ‘prophylactic doses’ are registered for each 
LMWH type as reflected by differences between authorised summary of product 
characteristics (SPC) in the United States and Europe, and also by differences in 
dosing regimens in randomized trials.4–11 The ACCP guidelines provide no 
recommendation regarding dose or type of LMWH for thrombosis prophylaxis. 
 
Multiple systematic reviews have evaluated LMWH for thrombosis prophylaxis in 
specific patient groups, such as oncological patients 12–14, orthopedic patients 11,15, 
and others.16–19 While evaluations of risks of bias are vital for any systematic review, 
these were parsimoniously considered. Further, only one systematic review, in 
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critically ill patients, used trial sequential analysis (TSA) 17, while the others did not 
apply any methods to account for risks of random error.12–19 No review evaluated 
benefits and harms associated with specifically a low or intermediate prophylactic 
LMWH dose. 
 
Our aim was to perform a systematic review with meta-analyses and TSA of 
randomized clinical trials (RCTs) according to The Cochrane Handbook for 
Systematic Reviews of Interventions comparing the benefits and harms of a 
predefined intermediate dose LMWH versus placebo or no treatment in patients at 




This systematic review was conducted according to a prepublished protocol on 
PROSPERO (CRD42016036951) following recommendations of The Cochrane 
Handbook for Systematic Reviews of Interventions and reported according to the 




We considered all RCTs for inclusion irrespective of language, blinding, publication 
status, or sample size. Quasi-randomized trials and observational studies were 
excluded. Only trials with adult patients at risk for VTE allocated to intermediate dose 
LMWH, placebo, or no treatment were eligible for inclusion, regardless their 





All trials that evaluated an intermediate dose of LMWH were considered, independent 
of the type of LMWH or duration of treatment. If different LMWHs or (weight adjusted) 
doses were used in one trial or even in one patient, we classified the trial according 
to what was used most frequently. Trials that evaluated ultra-low-molecular-weight 
heparin were included as well. We a priori defined ‘low’ and ‘intermediate’ dose 
LMWH in our protocol according to the SPCs as approved by the Food and Drug 
Administration, the European Medicines Agency and national authorities (Table 1 
and Suppl. Table 1).4–10 The control intervention was either placebo or no treatment.  
 
Outcomes 
All outcomes were graded according to the patients’ perspective following the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
approach (Suppl. Table 2).22 The primary outcome was all-cause mortality at 
maximum follow-up. Secondary outcomes were serious adverse events (SAE), 
symptomatic VTE, VTE screening (VTE diagnosed through screening of all patients 
in the trial), major bleeding, and heparin-induced thrombocytopenia (HIT). SAE was 
defined as a composite outcome measure summarizing all serious events 
necessitating an intervention, operation, or prolonged hospital stay according to the 
International Council for Harmonisation - good clinical practice guideline.23 To assess 
the balance between thrombosis and bleeding, VTE symptomatic and major bleeding 
were regarded SAE when they were counted as such by the original trial, but 
mortality was excluded. VTE included both DVT and PE. A diagnosis of DVT or PE 
was accepted when confirmed by imaging technique or autopsy. No distinction was 
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made according to location of DVT. Major bleeding and HIT were registered 
according to trial criteria, yet HIT required laboratory confirmation. 
 
Search strategy 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The 
Cochrane Library, PubMed/MEDLINE, EMBASE and Web of Science (Suppl. Table 
3). We searched the references of the identified trials and systematic reviews to 
identify any further relevant trials. Finally, we searched the World Health Organization 
trial platform and ClinicalTrials.gov for on-going trials.  
 
Study selection and data extraction 
Two authors independently identified trials for inclusion. Any indication for thrombosis 
prophylaxis was eligible. Trials excluded based on full text were listed with reasons 
for exclusion. We extracted characteristics of the trials (year of conduct and 
publication, country, numbers of participating sites and patients enrolled), participants 
(age, sex, inclusion and exclusion criteria), interventions (type, dose and duration of 
LMWH), and outcome. Corresponding authors were contacted in case of unclear or 
missing data. We resolved differences in opinion through discussion. 
 
Bias risk assessment 
Two authors independently assessed the risks of bias of the trials according to The 
Cochrane Handbook for Systematic Reviews of Interventions.20 The following risk of 
bias domains were extracted from each trial: sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessors, 
incomplete outcome data, selective outcome reporting, and other bias. Trials were 
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classified as having overall low risk of bias if all the domains were assessed at low 
risk. Trials were considered to have overall high risk of bias if one or more of the bias 
risk domains were assessed as unclear or high risk of bias.24  
 
Statistical analysis 
We performed the meta-analyses according to The Cochrane Handbook for 
Systematic Reviews of Interventions using the software package Review Manager 
5.3.5.20 The analyses were performed on an intention-to-treat basis whenever 
possible. For dichotomous variables we calculated risk ratios (RR) with trial 
sequential analysis-adjusted confidence intervals (TSA-adjusted CI) if there were two 
or more trials for an outcome. For rare events (<5% in the control group) we 
calculated odds ratios (OR) or Peto’s OR in case of very rare events (<2% in the 
control group), each with TSA-adjusted CI. TSA-adjusted CI excluding 1 were 
considered statistically significant. In case of statistical significant RR we calculated 
Number Needed to Treat (NNT) or Number Needed to Harm (NNH). 
 
We used a fixed-effect and a random-effects model for meta-analysis in the presence 
of two or more trials included under the outcomes. In case of discrepancy between 
the two models, we reported the results of both models. Considering the anticipated 
abundant clinical heterogeneity, we emphasized the random-effects model except if 
one or two trials dominated the evidence. Heterogeneity was measured by 
inconsistency (I2) and diversity (D2) and explored by the chi-squared test with 
significance set at p-value of 0.10.25,26 We used funnel plots to explore small trial bias 




Trial sequential analysis 
TSA is analogue to the interim analysis in a single randomized trial.27 TSA combines 
information size estimation for meta-analysis (cumulated sample size of included 
trials) with an adjusted threshold for statistical significance in the cumulative meta-
analysis.28–31 This adjusted threshold is more conservative when data are sparse and 
becomes progressively more lenient as the cumulated sample size approaches the 
estimated required information size.30,32 We performed TSA on all outcomes to 
account for the risk of type-I error and to provide information on how many more 
patients need to be included in further trials. Analyses were conducted using TSA 
software 0.9.5.10 Beta.33 We performed TSA with an overall type-I error of 5% and a 
power of 90%. The estimated required information size was calculated using the 
variance according to the meta-analytic model corresponding to the diversity adjusted 
information size (DIS), suggested by a relative risk reduction (RRR) of 10%. We 
calculated the model variance based diversity (D²) adjusted required information size 
since the heterogeneity adjustment with I2 tends to underestimate the required 
information size.25 The TSA was conducted using the unweighted control event 
proportion calculated from the actual meta-analyses. For all outcomes, we reported 
the CI adjusted for sparse data and repetitive testing, which we described as the 
TSA-adjusted CI.  
 
Sensitivity analysis 
Sensitivity TSA was conducted for all outcomes using a RRR suggested by the meta-
analysis of the included trials. If D² equalled zero we performed a sensitivity TSA 
using a D² of 25%. Additionally, trials evaluating types of LMWH that we were unable 





We used GRADE to assess the quality of the body of evidence associated with each 
outcome.22 The quality measure of a body of evidence considers within-study risk of 





The search was last updated on December 1st, 2018 and generated 9644 hits 
(Suppl. Table 4). Screening of reference lists and contacting authors revealed two 
additional hits. After removing duplicates and screening of titles and abstracts 523 
hits remained of which 457 were excluded based on full text. The remaining 66 
records reported 70 randomized trials and all fulfilled the eligibility criteria for 
inclusion. 34–99 
 
Characteristics of included studies  
Two trials were excluded from analyses for reporting surrogate or unclear 
outcomes.70,93 Two reports were translated (Chinese and French) 48,95 and six trials 
were published as abstract only. 37,68,70,85,92,99 Six trials evaluated types of LMWH 
which we were unable to classify either as ‘low’ or ‘intermediate’ dose; these were 
excluded from the primary analyses and included in sensitivity analyses as ‘LMWH 
dose undefined’ (Suppl. Table 5). 35,40,48,60,66 Eventually, 70 trials were included in this 
systematic review and 68 trials contributed data to the meta-analyses. We identified 




There were 36 single-center and 34 multicenter trials (Suppl. Table 7). Two trials 
used a four-arm design and five trials used a three-arm design; all other trials used a 
two-arm parallel group design. A variety of types of patients were evaluated by the 
trials, including ambulatory oncological patients (21 trials), surgical patients (15 
trials), orthopedic or immobilized patients (20 trials), acutely ill medical patients (6 
trials), neurological patients (3 trials) and others such as pregnant women at high risk 
of VTE or patients with cirrhotic liver disease (6 trials) (Suppl. Table 7). Eight different 
types of LMWH were evaluated; enoxaparin and dalteparin were most commonly 
used (Suppl. Table 7). LMWH was compared to placebo (37 trials) or to no 
intervention (33 trials). Duration of follow-up varied from 7 days to 5 years.  
 
Bias risk assessment 
Random sequence generation was assessed as low risk of bias in 39 trials (54%); 
allocation concealment in 41 trials (59%); blinding of participants and personnel in 31 
trials (44%); blinding of outcome assessors in 38 trials (54%); incomplete outcome 
data in 49 trials (70%), and selective outcome reporting in 50 trials (71%). A total of 
18 trials (26%) were classified as having an overall low risk of bias (Table 2). 
 
Outcomes 
For each outcome, the pooled intervention effects with TSA-adjusted CI were 
calculated, first for the trials with overall low risk of bias, second for all trials 
irrespective their risk of bias. Further, a priori defined subgroup effects were 






All-cause mortality at maximum follow-up 
Thirty-seven randomized trials with 24,732 patients reported all-cause mortality, with 
follow-up varying from 7 days to 5 years (Fig 1). Overall mortality proportions were 
18.6% in the LMWH group and 19.2% in the control group. The pooled intervention 
effect estimate of all RCTs suggested an overall beneficial effect in TSA (RR 0.96; 
TSA-adjusted CI 0.94 to 0.98; I2 0%; D2 0%; Table 3) and conventional meta-analysis 
(RR 0.94; CI 0.90 to 0.98; I2 12%; Table 3). Control event rates varied from 0.8% 
(orthopedics) to 76.6% (ambulatory cancer patients) and the overall effect estimate 
was primarily driven (83.4%) by the subgroup of ambulatory cancer patients receiving 
LMWH as anticancer treatment (Fig 1). We conducted a sensitivity analysis excluding 
this subgroup. When considering the remaining twenty-nine trials, TSA was not 
associated with a lower risk of all-cause mortality in the trials with low risk of bias (RR 
1.00; TSA-adjusted CI 0.76 to 1.31; I2 0%; D2 0%; Table 3) or in all trials regardless 
of bias risk (RR 0.99; TSA-adjusted CI 0.84 to 1.16; I2 0%; D2 0%; Table 3). Results 
from conventional meta-analyses and sensitivity analyses confirmed the above 
results and subgroup analyses on LMWH type, length of intervention period, and 
length of follow-up showed no statistically significant tests of interaction.  
 
Secondary outcomes 
Serious adverse events 
Sixteen randomized trials with 10,670 patients reported data on SAE. The incidence 
of SAE was 4.8% in the LMWH group and 4.2% in the control group. In the trials with 
overall low risk of bias, 5.4% of the required information size was accrued with low 
statistical heterogeneity, and no statistically significant intervention effect was found 
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(RR 1.21; TSA-adjusted CI 0.42 to 3.45; I2 0%; D2 0%; Table 3). All conventional and 
sensitivity analyses confirmed the absence of a significant intervention effect on SAE 
(Table 3). Subgroup analyses showed no statistically significant tests of interaction. 
 
Symptomatic venous thromboembolism 
Thirty-six randomized trials with 24,195 patients reported data on symptomatic 
venous thromboembolism (Fig 2). The incidence of symptomatic VTE was 1.6% in 
the LMWH group and 2.9% in the control group. TSA could not be conducted when 
only including trials with overall low risk of bias since less than 5% of the required 
information size was accrued. When considering all trials approximately 18.3% of the 
required information size was reached and a statistically significant beneficial 
intervention effects was found (OR 0.59; TSA-adjusted CI 0.53 to 0.67; I2 0%; D2 0%; 
NNT 76; 95% CI 60-106; Table 3; Fig 3). These results were confirmed in two out of 
three sensitivity TSA’s and in the conventional analyses of all trials (Table 3). 
Subgroup analyses showed no significant tests of interaction. 
 
Major bleeding 
Fifty-seven randomized trials with 28,182 patients reported data on major bleeding 
(Fig 4). The incidence of major bleeding was 1.2% in the LMWH group and 0.7% in 
the control group. TSA could not be conducted since less than 5% of the required 
information size was accrued (all trials and overall low risk of bias). Conventional 
analyses of the trials with overall low risk of bias showed no statistically significant 
increase in major bleeding (Peto OR 1.35; 95% CI 0.81 to 2.26; I2 3%; Table 3). 
When considering all trials regardless of bias risk, sensitivity TSA with RRR 
estimated by the meta-analysis found a statistically significant harmful intervention 
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effect (Peto OR 1.66; TSA-adjusted CI 1.31 to 2.10; I2 0%; D2 0%; NNH 212; 95% CI 
142 to 393; Table 3; Fig 5) which was confirmed by conventional meta-analysis (Peto 
OR 1.66; 95% CI 1.30 to 2.12; I2 20%; Table 3). No subgroup differences were 
detected.  
 
Venous thromboembolism screening 
Forty-two randomized trials with 13,963 patients reported data on VTE screening. 
The incidence of VTE screening was 6.3% in the LMWH group and 12.0% in the 
control group. In the TSA of trials with overall low risk of bias, 5.1% of the required 
information size was accrued, with moderate statistical heterogeneity, and no 
statistically significant intervention effect was found (RR 0.57; TSA-adjusted CI 0.14 
to 2.32; I2 52%; D2 54%; Table 3). The sensitivity TSA with RRR estimated by the 
meta-analysis found that LMWH was associated with a statistically significant 
beneficial intervention effect (RR 0.57; TSA-adjusted CI 0.39 to 0.82; I2 52%, D2 
54%; Table 3). When considering all trials a statistically significant beneficial effect 
was found (RR 0.52; TSA-adjusted CI 0.44 to 0.61; I2 0%; D2 0%; NNT 18; 95% CI 
15 to 21; Table 3), confirmed by all conventional meta-analyses and sensitivity 
analyses. Subgroup analyses based on the duration of the interventions showed a 
statistically significant test of interaction (p=0.02), indicating a larger beneficial 
intervention effect in the subgroup of trials treating patients for less than 30 days (RR 
0.47; CI 0.42 to 0.53; I2 0%) compared to the subgroup of trials treating patients for 







Thirteen randomized trials with 10,340 patients reported data on heparin-induced 
thrombocytopenia, but no objective laboratory HIT confirmation was reported so we 
were unable to perform analyses.  
 
Small trial bias 
Funnel plots showed no clear arguments for small trial bias in all but one outcome 
(Suppl. Figure 6a-e). The funnel plot of ‘VTE screening’ was asymmetric, possibly 
indicating publication bias.  
 
GRADE approach 
The quality of the evidence was assessed as low to moderate for all outcomes based 




We evaluated the benefits and harms of intermediate dose LMWH for thrombosis 
prophylaxis in patients at risk for VTE. We included 70 RCTs with 34,046 randomized 
patients of which 18 trials (26%) had overall low risk of bias. Analyses indicated that 
compared to placebo or no treatment intermediate dose LMWH was associated with 
a small decrease in mortality which disappeared in a sensitivity analysis excluding 
trials that evaluated LMWH for anticancer treatment. Intermediate dose LMWH 




Our findings on mortality are in line with results from previous systematic reviews.13–
17 The overall effect estimate obtained by pooling all RCTs did suggest lower 
mortality associated with intermediate dose LMWH. However, we decided post hoc to 
do a sensitivity analysis excluding eight RCTs that assessed ambulatory cancer 
patients who received LMWH as adjuvant to their cancer treatment from the primary 
outcome analysis as this subgroup had a substantially higher control event rate of 
mortality of 76.6%, contributed 83.4% weight and was the main driving force for the 
overall pooled effect estimate and its significance. Although in any meta-analysis a 
certain amount of clinical heterogeneity is unavoidable, the observed differences in 
control event rates suggest potentially relevant clinical differences between patient 
populations. For this reason we deemed it inappropriate to rely solely on the overall 
pooled effect estimate as this could lead to spurious inferences about the effect on 
mortality in other subgroups with fewer observed events. This decision was primarily 
based on clinical considerations as we observed low statistical heterogeneity and 
subgroup analyses showed no statistically significant tests of interaction. 
 
Robustness of conclusions was evaluated by several additional analyses. We 
conducted our main analysis with TSA of all outcomes based on an a priori 
hypothesized 10% RRR as specified in our protocol. Sensitivity analyses with meta-
analytic estimates of trials with overall low risk of bias suggested a 41% RRR for 
symptomatic VTE and a 35% RRI for major bleeding. Although even this low risk of 
bias RRR estimate may still be overestimated, the a priori specified 10% RRR for the 
TSA used in our analyses may have been too conservative and alternatively one 
could probably base the conclusions on the TSA anticipating the RRR estimated from 
the trials with low risk of bias. Further, in subgroup analyses the bias effect seems 
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limited since the meta-analytic point-estimates are rather similar across all outcomes 
regardless of the bias risks of the trials, suggesting that we may rely on the more 
precise estimates derived from all the trials. These sensitivity and subgroup analyses 
strengthen the conclusion of a beneficial intervention effect on VTE but also indicate 
a harmful effect on major bleeding. The NNT for preventing one case of symptomatic 
VTE is 76 compared to a NNH of 212 for major bleeding, which suggests the balance 
favors the intervention. As we did not detect any significant subgroup differences we 
cannot make inferences about the benefit to harm ratio in specific patient 
populations.  
 
The main strength of this review is its systematic approach according to The 
Cochrane Handbook for Systematic Reviews of Interventions, following a previously 
published protocol with assessment of the risks of systematic and random errors, 
and, most important, incorporation of error risks in the primary analyses and 
conclusions.20 We systematically explored the associations between bias risks and 
intervention effects in all outcomes, while previous reviews did not incorporate the 
bias risks in their results and conclusions.11,14,15,17  
 
This systematic review is, however, associated with important limitations. We 
provided a comprehensive overview of the effects of intermediate dose LMWH in all 
patient populations. As we wished to evaluate the overall effect of intermediate dose 
LMWH in patients at increased risk for VTE we deliberately included all types of 
patients. Generally statistical heterogeneity was low, but obviously clinical 
heterogeneity of patients, including control event rates, durations of interventions and 
follow-up was substantial. For reasons described above we made a deviation from 
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our protocol and decided post hoc, in a sensitivity analysis, to exclude trials which 
assessed overall mortality in ambulatory cancer patients receiving LMWH as an 
anticancer treatment from the primary outcome analysis. We did include these trials 
as planned in analyses of the other outcomes since they also provide data on VTE or 
major bleeding events. 
 
Second, we included both VTE and major bleeding in our definition of SAE to 
evaluate the balance between thrombosis and bleeding. While we excluded mortality, 
our outcome SAE by definition included double counts of VTE and bleeding events 
since these were also considered separately. Most trial reports were unclear about 
the definitions and the numbers of SAE and we were often unable to distinguish 
whether VTE or major bleeding had been incorporated in the SAE counts. This made 
a direct evaluation of the balance between thrombosis and bleeding impossible. 
Third, we accepted all events of VTE proven by objective testing, but we did not 
make a distinction according to DVT location (i.e. distal versus proximal or lower 
versus upper extremity). This may have contributed to heterogeneity in our VTE 
outcome definition. However, many of the original trial reports did not provide details 
on DVT locations, which prevented such detailed evaluations. 
 
Conclusions  
The use of intermediate dose LMWH for thrombosis prophylaxis compared to 
placebo or no treatment was associated with a small statistically significant reduction 
of all-cause mortality, which however disappeared in a sensitivity analysis excluding 
trials that evaluated LMWH for anticancer treatment. Intermediate dose LMWH 
provides benefits in terms of VTE prevention while it increases major bleeding, as 
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suggested by consistent effects in a broad range of populations estimated by 
randomized trials with overall low risks of systematic and random errors.  
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Fig 1. Forest plot of all-cause mortality 
Fig 1 caption: Forest plot of all-cause mortality at maximal follow-up of LMWH 
prophylaxis compared to placebo or no treatment in patients at risk for VTE, stratified 
according to population, including ambulatory cancer patients receiving LMWH for 
anticancer treatment. Size of the squares reflects the weight of the trial in the pooled 
analysis. Horizontal bars represent 95% confidence intervals 
 
Fig 2. Forest plot of VTE symptomatic 
Fig 2 caption: Forest plot of VTE symptomatic at maximal follow-up of LMWH 
prophylaxis compared to placebo or no treatment in patients at risk for VTE, stratified 
according to the population type. Size of the squares reflects the weight of the trial in 
the pooled analysis. Horizontal bars represent 95% confidence intervals 
 
Fig 3. Trial sequential analysis of VTE symptomatic 
Fig 3 caption: Trial sequential analysis of VTE symptomatic at maximal follow-up of 
LMWH compared to placebo or no treatment in patients at risk for VTE. The required 
information size of 132,001 patients was calculated using the predefined α=0.05 (two 
sided), β=0.10 (power 90%), D2=0%, an anticipated relative risk reduction of 10% 
and an event proportion of 2.86% in the control arm. The cumulative Z-curve is 
constructed using a random effects model, and each cumulative Z-value is calculated 
after inclusion of a new trial (as represented by black dots). The dotted horizontal 
lines represent the conventional naïve boundaries for benefit (positive, Z = +1.96) or 
harm (negative, Z = -1.96). The etched lines represent the trial sequential boundaries 
for benefit (positive), harm (negative), or futility (middle triangular area). The 
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cumulative Z-curve crosses the TSA boundary for benefit, indicating future trials are 
very unlikely to change conclusions. 
 
Fig 4. Forest plot of major bleeding 
Fig 4 caption: Forest plot of major bleeding at maximal follow-up of LMWH 
prophylaxis compared to placebo or no treatment in patients at risk for VTE, stratified 
according to the population type. Size of the squares reflects the weight of the trial in 
the pooled analysis. Horizontal bars represent 95% confidence intervals. 
 
Fig 5. Trial sequential analysis of major bleeding 
Fig 5 caption: Trial sequential analysis of major bleeding at maximal follow-up of 
LMWH compared to placebo or no treatment in patients at risk for VTE. The required 
information size of 42,077 patients was calculated using the predefined α=0.05 (two 
sided), β=0.10 (power 90%), D2=0%, an anticipated relative risk reduction of -35% 
(as anticipated by the low risk of bias trials) and an event proportion of 0.7% in the 
control arm. The cumulative z-curve, constructed using a random-effects model, 
crosses the TSA boundary for harm, indicating future trials are very unlikely to 





Table 1. Classification of low and intermediate dose prophylactic ranges 
 A priori defined prophylaxis dose limits Dose as used in 
included trials 
 
Low dose Intermediate dose 
Nadroparin (Fraxiparine) < 5700 IU ≥ 5700 IU 5700 - 7600 IU a 
Dalteparin (Fragmin) < 5000 IU ≥ 5000 IU 5000 IU b 
Enoxaparin (Lovenox) < 40 mg  ≥ 40 mg 40 mg - 1 mg/kg 
Tinzaparin (Innohep) < 4500 IU ≥ 4500 IU 4500 IU c 
Parnaparin (Fluxum) < 4250 IU ≥ 4250 IU Not used 
Bemiparin (Zibor) < 3500 IU ≥ 3500 IU 3500 IU 
Reviparin (Clivarin) < 3436 IU ≥ 3436 IU Not used 
Table 1 footnote: IU: International Units; mg: milligrams; a one study by van 
Doormaal et al91 used weight-dependent doses up to 15.200 IU intended as 
prophylaxis; b one study by Maraveyas et al69 used 200 IU/kg intended as 





































































































































































































Agnelli 1998 Low Low Low Low Low Low 
Agnelli 2012 Low Low Low Low Low Low 
Ahuja 2016 Low Unclear High Unclear Unclear Low 
Alalaf 2015 Low Low High Unclear Low Low 
AlGahtani 2015 Unclear Unclear Unclear Unclear Unclear Unclear 
Altinbas 2004 Unclear Unclear High Low Low Unclear 
Cesarone 2002 Unclear Unclear Unclear Unclear high Low 
Chin 2009 Unclear Unclear Unclear Low Unclear High 
Christensen 2017 Low High High Unclear High Low 
Conte 2003 Unclear Unclear Low Unclear Unclear Low 
Dahan 1986 Unclear Unclear Low Unclear Low Low 
Dar 2012 Unclear Unclear Low Unclear Unclear Unclear 
Ek 2018 Low Low High Unclear Low Low 
Elias 1990 Unclear Unclear High Unclear Low Low 
Fuji 2008a Unclear Unclear Unclear Low High Low 
Fuji 2008b Unclear Unclear Unclear Low High Low 
Gagneux 1987 Unclear Unclear Unclear Unclear Unclear Unclear 
Gates 2004a Low Low Low Low Low Low 
Gates 2004b Low Low Low Low Low Low 
Goel 2009 Low Low Low Low Low Low 
Haas 2012a Low Low Low Low Low Low 
Haas 2012b Low Low Low Low Low Low 
Halim 2014 Low Low High Low Low High 
Ho 1999 Unclear Low High Low High Low 
Intiyanaravut 2017 Unclear Low High Low Unclear Low 
Jorgensen 1992 Unclear Unclear Low Unclear Low Low 
Jung 2018 Low Low High Unclear Low High 
Kakkar 2004 Low Low Low Low Low Low 
Kakkar 2011 Low Low Low Low Low Low 
Kalodiki 1993 Unclear Low Low Low Unclear Low 
Karthaus 2006 Low Low Low Low Low Low 
Khorana 2017 Low Low High Low Low Low 
Kim 2016 Low Low Low Low High High 
Kiudelis 2010 Unclear Unclear High Unclear Low High 
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Klerk 2005 Low Low Low Low Low Low 
Kock 1995 Unclear Unclear High Unclear Low Low 
Lapidus 2007 Unclear Low Low Unclear Low Low 
Leclerc 1992 Low Low Low Low Low Low 
Lecumberri 2013 Low Low High High Low Low 
Lederle 2006 Low Low Low Low Low Low 
Leizorovicz 2004 Unclear Unclear Low Low High Low 
Levine 1996 Low Low Low Low Low Low 
Macbeth 2016 Low Low High Unclear Low Low 
Maraveyas 2012 Low Low High High Low Low 
Maurer 2009 Unclear Unclear Unclear Unclear Unclear High 
Meyer 2017 Low Low High Low Low High 
Michot 2002 Unclear Low High Low Low Low 
Modesto-Alapont 
2006 
Low Low High Unclear Low Low 
Pelzer 2015 Low Low High High Low Low 
Perry 2010 Low Low Low Low Low Low 
Prins 1989 Unclear Unclear Low Unclear Low Low 
Rodger 2015 Low Low Low Low Low Unclear 
Rodger 2016 Low Low High Low Low Unclear 
Samama 1997 Low Low Low Low Low Low 
Samama 1999 Unclear Low Low Low Low Low 
Sang 2018 Low Unclear High Unclear Low High 
Selby 2015 Low Low Low Low Low Low 
Sideras 2006 Low Low High Unclear Low Low 
Sourmelis 1995a Unclear Unclear Low Unclear Unclear Unclear 
Sourmelis 1995b Unclear Unclear Low Unclear Unclear Unclear 
Torholm 1991 Unclear Unclear Low Unclear Low Low 
Turpie 1986 Unclear Unclear Low Low Low Low 
Vadhan-Raj 2013 Unclear Unclear High Unclear Low Low 
van Doormaal 2011 Unclear Low High Low Low Low 
Verso 2005 Low Low Low Low Low Low 
Villa 2012 Low Low High Low Low Low 
Wang 2018 Unclear Unclear High High Unclear High 
Warwick 1995 Unclear Unclear High Low Unclear High 
Xia 2011 Low Unclear Unclear Unclear Low High 
Zwicker 2013 Unclear Unclear High Unclear Low Low 
 
Table 2 footnote: Review of authors’ judgements about each risk of bias domain for 
each included study.  
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Conventional analysis a Main analysis TSA a 
RRR 10%, ß 90%, D2 model 
variance based 
Sensitivity TSA a 
RRR based on low risk trials, ß 
90%, D2 model variance based 
Sensitivity TSA a 
RRR 10%, ß 90%,D2 25% 
Mortality       
Including ‘LMWH for 
anticancer treatment’ 
Low bias risk 10 (10,770) RR 0.92 (0.86 to 0.98) RR 0.92 (0.83 to 1.01) RR 0.92 (0.81 to 1.04) RR 0.92 (0.82 to 1.03) 
Excluding ‘LMWH for 
anticancer treatment’ 
Low bias risk 8 (10,083) RR 1.00 (0.89 to 1.13) RR 1.00 (0.76 to 1.31) Not performed (RRR 0%) RR 1.00 (0.73 to 1.37) 
       
Including ‘LMWH for 
anticancer treatment’ 
All 37 (24,732) RR 0.94 (0.90 to 0.98) RR 0.96 (0.94 to 0.98) RR 0.96 (0.94 to 0.99) RR 0.96 (0.94 to 0.99) 
Excluding ‘LMWH for 
anticancer treatment’ 
All  29 (20,288) RR 0.99 (0.90 to 1.10) RR 0.99 (0.84 to 1.16) Insufficient data (<5% of DIS) RR 0.99 (0.82 to 1.19) 
       
SAE       
 Low bias risk 4 (8,741) RR 1.21 (0.93 to 1.56) RR 1.21 (0.42 to 3.45) RR 1.21 (0.68 to 2.14) Insufficient data (<5% of DIS) 
 All 16 (10,670) RR 1.16 (0.99 to 1.37) RR 1.16 (0.60 to 2.23) RR 1.16 (0.91 to 1.47) RR 1.16 (0.60 to 2.23) 
       
VTE symptomatic       
 Low bias risk 11 (10,759) Peto OR 0.59 (0.39 to 0.91) b Insufficient data (<5% of DIS) b Peto OR 0.59 (0.30 to 1.18) b Insufficient data (<5% of DIS) b 
 All 36 (24,195) OR 0.58 (0.46 to 0.73) OR 0.59 (0.53 to 0.67) OR 0.59 (0.48 to 0.73) OR 0.59 (0.27 to 1.29) 
       
Major bleeding       
 Low bias risk 14 (11,631) Peto OR 1.35 (0.81 to 2.26) b Insufficient data (<5% of DIS) b Peto OR 1.35 (0.17 to 10.85) b Insufficient data (<5% of DIS) b 
 All 57 (28,182) Peto OR 1.66 (1.30 to 2.12) b Insufficient data (<5% of DIS) b Peto OR 1.66 (1.31 to 2.10) b Insufficient data (<5% of DIS) b 
       
VTE screening       
 Low bias risk 6 (1,737) RR 0.57 (0.40 to 0.80) RR 0.57 (0.14 to 2.32) RR 0.57 (0.39 to 0.82) Not performed (D2 >25%) 
 All 42 (13,963) RR 0.50 (0.44 to 0.57) RR 0.52 (0.44 to 0.61) RR 0.52 (0.46 to 0.58) RR 0.52 (0.43 to 0.62) 
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Table 3 footnote: ß: power; D2: diversity; DIS: diversity adjusted information size; OR: odds ratio; RR: relative risk; RRR: relative 
risk reduction; SAE: serious adverse events; TSA: trial sequential analysis; a Small discrepancies of the intervention effect estimates 
between the traditional RevMan meta-analyses and the TSA adjusted results may occur due to different pooling methods (for 
example the inclusion of zero-event trials in TSA analyses); b Fixed-effect model 
 
 
